kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant SARS-CoV-2 Spike RBD (K417T, E484K, N501Y), Mouse IgG1 Fc Tag (MALS verified), 1mg  

Recombinant SARS-CoV-2 Spike RBD (K417T, E484K, N501Y), Mouse IgG1 Fc Tag (MALS verified), 1mg

Recombinant SARS-CoV-2 Spike RBD (K417T, E484K, N501Y), AA Arg 319 - Lys 537, expressed from human 293 cells (HEK293), Mouse IgG1 Fc Tag (MALS verified)

Synonyms: Recombinant, Spike, S protein RBD, Spike glycoprotein Receptor-binding domain, S glycoprotein RBD, Spike protein RBD

More details


Availability: within 10-14 days

2 600,00 €

It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Recombinant SARS-CoV-2 Spike RBD (K417T, E484K, N501Y), Mouse IgG1 Fc Tag (SPD-C5257) is expressed from human 293 cells (HEK293). It contains AA Arg 319 - Lys 537 (Accession # QHD43416.1(K417T, E484K, N501Y)).
Predicted N-terminus: Arg 319

Molecular Characterization
This protein carries a mouse IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 50.8 kDa. The protein migrates as 55-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 0.1 EU per μg by the LAL method.

>95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in 50 mM Tris,100 mM Glycine, 25 mM Arginine,150 mM NaCl,pH7.5. Normally trehalose is added as protectant before lyophilization.

Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "Decline of antibody titres three months after two doses of BNT162b2 in non-immunocompromised adults"
Erice, Varillas-Delgado, Caballero
Clin Microbiol Infect (2021)
(2) "Dynamics prediction of emerging notable spike protein mutations in SARS-CoV-2 implies a need for updated vaccines"
Al-Zyoud, Haddad
Biochimie (2021)
(3) "The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice"
Sun, He, Zhang et al
Signal Transduct Target Ther (2021) 6 (1), 340
Showing 1-3 of 1501 papers.
Please refer to product data sheet.